NATCO Pharma Limited has issued an update regarding the anticipated launch of its generic version of Risdiplam in India. The company has received significant interest from investors and patients concerning the availability, pricing, and legal status of the drug.
As per the latest legal developments, the Delhi High Court’s Single Judge had earlier, on March 24, 2025, rejected Roche’s plea to block NATCO from launching the drug. However, Roche has appealed this decision. The Appellate Bench has currently directed both parties to maintain the status quo, and the matter remains sub judice.
Due to the ongoing legal proceedings, NATCO has refrained from commenting further on the case. The company reiterated its commitment to launching Risdiplam only after obtaining a favorable and clear directive from the Appellate Bench, which is expected soon.
In line with its stance presented before the court, NATCO has announced the Maximum Retail Price (MRP) of its generic Risdiplam at ₹15,900. Additionally, the company plans to support accessibility by offering discounts through a dedicated patient access program, aiming to assist deserving patients in need.
